DYAI Stock Analysis: Buy, Sell, or Hold?
DYAI - Dyadic International, Inc.
$0.80
0.11 (16.70%)
▲
5d:
+13.86%
30d:
+15.35%
90d:
-1.67%
BUY
MODERATE Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: May 20, 2026
0d
Get Alerted When DYAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DYAI shows positive signals but monitor for confirmation. Market pricing in 30.6% decline. Moderate conviction.
💡 BUY OPPORTUNITY: DYAI shows positive signals but monitor for confirmation. Market pricing in 30.6% decline. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DYAI is currently trading at $0.80, which is considered extended relative to its 30-day fair value range of $0.69 to $0.76. From a valuation perspective, the stock is trading at a discount (Forward PE: 20.5) compared to its historical average (61.2). Remarkably, the market is currently pricing in an annual earnings decline of 30.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, DYAI is in a downtrend. Immediate support is located at $0.66, while resistance sits at $0.83. The stock is showing strong short-term momentum, up 16.7% recently.
Market Sentiment: DYAI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.00 (+779.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DYAI is in a downtrend. Immediate support is located at $0.66, while resistance sits at $0.83. The stock is showing strong short-term momentum, up 16.7% recently.
Market Sentiment: DYAI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.00 (+779.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.69 -
$0.76
Company Quality Score
56/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: Strong upward momentum (+16.7%)
- BULLISH: Trading 779.8% below Wall St target ($6.00)
Trading Range Analysis
30-Day Trading Range
$0.69 -
$0.76
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.66
Resistance Level
$0.83
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.48
Wall Street Target
$6.00
(+779.8%)
Revenue Growth (YoY)
182.3%
Profit Margin
-191.5%
Valuation Discount vs History
-30.6% cheaper
PE vs Historical
20.5 vs 61.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-30.6%
(market-implied from PE analysis)
1-Year Target
$0.61
(-10%)
2-Year Target
$0.55
(-19%)
3-Year Target
$0.50
(-27%)
3-Yr Target (if PE normalizes)
(PE: 20→61)
$1.49
(+118%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 20.5 to 61.2
Stabilization Target:
$2.04
(+198.8%)
PE Expansion Potential:
+198.8%
Share & Embed Analysis
Last updated: June 15, 2026 4:47 PM ET
Data refreshes hourly during market hours. Next update: 5:47 PM
Data refreshes hourly during market hours. Next update: 5:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DYAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 63 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$103 | 58 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$123 | 52 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 53 HOLD |
